Impact Biomedical (IBO) Revenue (2022 - 2026)
Impact Biomedical (IBO) posted Revenue of $7000.0 for Q1 2026, down 61.11% quarter-over-quarter from $18000.0 in Q3 2025.
Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Revenue for 3 consecutive years, with $7000.0 the latest figure, recorded in Q1 2026.
- Revenue for Q1 2026 came in at $7000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY), and the FY2022 annual result was $50000.0, changed N/A from the prior year.
- Revenue was $7000.0 for Q1 2026 at Impact Biomedical, down from $18000.0 in the prior quarter.
- Over five years, Revenue peaked at $50000.0 in Q2 2022 and troughed at $7000.0 in Q2 2025.
- Average Revenue over 3 years is $20500.0, with a median of $12500.0 recorded in 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 896.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 1.51 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 2.99 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | 72.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 1.30 Bn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 1.17 Bn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Impact Biomedical | 50.66 Mn | 53.89 Mn | 6,000.00 | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2022 | 50,000.00 |